Related Experiment Video

Updated: Sep 11, 2025

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
06:58

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

5.1K

Association of SCN1A Gene Polymorphisms with Sodium Valproate Resistance in Pediatric Epilepsy: A Retrospective

Huiyu Wang1, Tingting Geng1, Na Deng1

  • 1Department of Pediatric Intensive Care Unit, Shiyan Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei Province, People's Republic of China.

Neuropsychiatric Disease and Treatment
|August 12, 2025
PubMed

Insights

Genetic variations in the SCN1A gene are linked to sodium valproate resistance in pediatric epilepsy. Specific SCN1A mutations correlate with reduced drug efficacy and increased seizure severity, paving the way for personalized treatments.

Area of Science:

  • Genetics
  • Pharmacogenomics
  • Pediatric Neurology

Background:

  • Epilepsy affects a significant portion of the Chinese population, with a notable percentage experiencing resistance to antiepileptic drugs.
  • Understanding genetic factors in sodium valproate resistance is crucial for developing personalized treatment strategies in pediatric epilepsy.

Purpose of the Study:

  • To investigate the association between SCN1A gene polymorphisms and sodium valproate resistance in pediatric epilepsy patients.
  • To explore the impact of these polymorphisms on plasma valproate concentrations and seizure types.

Main Methods:

  • Retrospective analysis of 89 pediatric patients with drug-resistant epilepsy, 89 with drug-responsive epilepsy, and 89 healthy controls.
  • Analysis of SCN1A gene polymorphisms and comparison across groups.
  • Evaluation of plasma valproate concentrations and multivariate logistic regression to identify resistance factors.

Main Results:

  • Significant differences in SCN1A genotype distributions were found for five loci (rs166859148, rs166894396, rs166848482, rs166915162, rs166870333-335) between groups.
  • Mutations at these loci correlated with sodium valproate resistance and, for rs166915162 and rs166870333-335, were associated with lower plasma valproate levels.
  • The rs166870333-335 variant was also linked to generalized seizure types in drug-resistant patients.

Conclusions:

  • SCN1A gene mutations, specifically at rs166859148, rs166894396, rs166848482, rs166915162, and rs166870333-335, may contribute to sodium valproate resistance in pediatric epilepsy.
  • Mutations in rs166915162 and rs166870333-335 are associated with reduced plasma valproate levels.
  • The rs166870333-335 mutation is linked to generalized seizure types in drug-resistant epilepsy, highlighting its clinical significance.
Abstract

Keywords:
SCN1A geneblood drug concentrationchildrendrug resistanceepilepsysodium valproate

More Related Videos

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

494
Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane07:38

Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane

Published on: March 30, 2015

9.3K

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
448
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
17.9K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.9K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
880
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
646
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.6K